• Gilead Sciences Presents New Data on HCV, HBV Treatment with Harvoni
  • RTT MolecularDX Launches Tests to Detect Drug-resistant Hepatitis Viruses
  • FDA Approves Sovaldi and Harvoni for Pediatric Hepatitis C Patients
  • ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431
  • New Study Investigates Link Between Viral Hepatitis and Parkinson’s Disease
  • Report Defines Plan to Prevent 90,000 Hepatitis B and C Deaths in US by 2030
  • European Public Health Alliance Joins Patent Opposition for HCV Treatment
  • Gilead’s Harvoni Cured 97% of Hepatitis C Patients in Real-world Study
  • HCV Gene Mutations Present New Challenges for Vaccine Development
  • HCV Infection May Increase Risk of Cataracts, Study Finds
  • Baby Boomers at Risk of Hepatitis C Infection Aren’t Getting Tested, Despite Official Prodding
  • Developing HCV Vaccine May Be Possible by Exposing Virus to Immune System Attack